Articles

  1. Glass Prefillable Syringe Solution Delivering Complex Biologics 5/9/2022

    BD Neopak™ XtraFlow™ Glass Prefillable Syringe solution leverages 8 mm needle length in combination with thin wall cannula to reduce pressure drop and enhance flow.

  2. Combination Products 4/28/2022

    Kymanox provides turnkey services to bring your product from concept to commercialization — and helps keep your product on the market. Kymanox has expertise in injectables (e.g., syringes, mechanical and electromechanical autoinjectors, wearable injectors, dual chamber systems, reconstitution systems), respiratory combination products (e.g., metered dose inhalers, dry powder inhalers, nasal sprays), and in ocular products (e.g., multi-dose containers, single-use injectables).

  3. Enabling The Delivery Of Complex Biologics With Ergonomic Solutions 4/21/2022

    The BD UltraSafe Plus™ passive needle guard for pre-filled ISO standard glass syringes is designed to support viscous drug delivery with ergonomics and drug visibility.

  4. Aseptic Manufacturing Services 3/23/2022

    Our system is ideally suited for the production of pre-clinical, clinical and niche commercial injectable products in vial, syringe, and cartridge formats.

  5. Lyophilization vs. Liquid Formation: Why Lyo Offers Advantages 3/8/2022

    Lyophilization offers some alluring advantages in today’s complex market, but its challenges require innovation and expertise to surmount.

  6. Pre-Formulation And Material Sciences 3/3/2022

    Our formulation development and material sciences experts have over 30 years’ experience in pre-formulation and solid state characterization.

  7. Nanosuspension Dosage Forms: Product Development & Scale Up 2/8/2022

    For drug nanosuspensions, parameters like stabilizer concentration, drug loading, milling speed, milling time, bead diameter/density, and temperature are important formulation and process variables.

  8. Considerations In Formulation Development Of Injectable Solutions 2/8/2022

    Injectable solutions offer an alternative to oral dosage form due to fast onset, reproducible PK/efficacy profile, high bioavailability, and suitability of administration under hospital setting.

  9. Considerations In Development & Manufacturing Of Complex Injectables For Early Phase Studies 2/7/2022

    A niche CDMO, with specialized technologies in complex injectable development, will have greater flexibility for successful manufacture of complex injectables in early phase development of therapeutic drugs.

  10. Sterile Formulation And Fill/Finish For Early-Phase Clinical Trials 1/28/2022

    Ascendia’s team of scientists have decades of combined experience in sterile supplies for clinical trials, making them expert at solving the most difficult formulation challenges.